Gofen 200 soft capsules 200 mg. №60

Description

Gofen 200 mg Storage
active substance: ibuprofen;

1 soft capsule contains ibuprofen 200 mg;

excipients: polyethylene glycol 600, potassium hydroxide, purified water;

gelatin capsule: gelatin, sorbitol, non-crystallizing solution (E 420), purified water.

Gofen 200 mg Dosage form
The capsules are soft.

Main physical and chemical properties: elongated soft capsules with a transparent shell of natural color, the contents of the capsule – a clear, colorless oily liquid.

Gofen 200 mg Pharmacotherapeutic group
Nonsteroidal anti-inflammatory and anti-rheumatic drugs. Derivatives of propionic acid.

ATX code M01A E01.

Pharmacological properties

Pharmacodynamics.

Has analgesic, antipyretic and anti-inflammatory effects. The mechanism of action is to inhibit the synthesis of prostaglandins – mediators of pain, inflammation and temperature response.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation with concomitant use of these drugs. Some pharmacodynamic studies have shown that single doses of ibuprofen 400 mg within 8 hours before or within 30 minutes of immediate-release acetylsalicylic acid (81 mg) reduced the effect of aspirin (acetylsalicylic acid) on thromboxane formation or aggregation by thromboxane. Although there is uncertainty about the extrapolation of these data to the clinical situation, it cannot be ruled out that regular long-term use of ibuprofen may reduce the cardioprotective effect of low doses of acetylsalicylic acid. In the case of unsystematic use of ibuprofen, such a clinically significant effect is considered unlikely.

Pharmacokinetics.

After oral administration, ibuprofen is rapidly absorbed from the digestive tract. The maximum concentration of the active substance in blood plasma is determined in 1‒2 hours after ingestion. Ibuprofen is metabolized in the liver, excreted by the kidneys (90%) unchanged and as metabolites, as well as bile. The half-life in healthy people is almost 1.8 hours, in patients with liver and kidney disease – 1.8-3.5 hours. Ibuprofen is actively (99%) bound to plasma proteins, slowly penetrating the synovial cavities, where its concentration may remain high, while the concentration in blood plasma decreases.

Indication
Symptomatic treatment of headache, toothache and intermittent menstrual pain.

Fever and muscle aches from colds.

Contraindication
Hypersensitivity to ibuprofen or to any of the components of the drug.
Patients with a history of bronchospasm, asthma, rhinitis, angioneurotic edema, or skin rash associated with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs).
Concomitant use with other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, should be avoided.
Patients with a history of gastrointestinal bleeding or perforation after NSAID use.
Gastric or peptic ulcer: two or more clear episodes of exacerbation of peptic ulcer disease or bleeding.
Patients with severe renal, hepatic or cardiac (NYHA class IV) insufficiency.
Children weighing less than 20 kg.
Patients with cerebrovascular or other active forms of bleeding.
Patients with unclear etiology of hematopoietic disorders.
Patients with impaired dehydration caused by vomiting, diarrhea, or insufficient fluid intake.
The last trimester of pregnancy.